New Antidepressant OKd by FDA

Tuesday, 01 Oct 2013 12:32 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

H. Lundbeck A/S and Takeda Pharmaceutical Co. (4502) won approval for the drug Brintellix to treat people with major depressive disorder, U.S. regulators said.
Major depressive disorder is one of the most common mental disorders in the U.S. affecting about 7 percent of U.S. adults each year, according to the National Institutes of Health. The condition interferes with a person’s ability to work, sleep, study, eat and enjoy once-pleasurable activities.

Editor's Note:
Natural Hormones Help Treat Heart Disease, Depression and Chronic Fatigue
“Since medications affect everyone differently, it is important to have a variety of treatment options available for patients who suffer from depression,” Mitchell Mathis, acting director of the Division of Psychiatry Products in the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research, said in a statement.
Peak sales of the drug may reach $1 billion to $2 billion and Lundbeck plans to hire more than 200 salespeople in the U.S. to market the medication, Chief Financial Officer Anders Gotzsche said in an interview in August. Sales of Brintellix may help offset losses from Lundbeck’s Lexapro that began facing generic competition in 2012. Lexapro went from generating $474 million in sales in 2011 to an estimated $8 million this year.
Lundbeck, based in Copenhagen, will co-promote the drug with Osaka, Japan-based Takeda.
Generic drugs are available to treat depression as well as Eli Lilly & Co. (LLY)’s Cymbalta and AstraZeneca Plc (AZN)’s Seroquel XR.
 

© Copyright 2014 Bloomberg News. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Comments
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
Find Your Condition
You May Also Like
Around the Web

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

NEWSMAXHEALTH.COM
© Newsmax Media, Inc.
All Rights Reserved